NCT07476677 2026-03-17
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT07450599 2026-03-05
CHINANEO
Bayer
Phase 2 Not yet recruiting
NCT07344779 2026-01-26
ROAD
Bayer
Not yet recruiting
NCT06660862 2026-01-08
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
University of Chicago
Phase 4 Not yet recruiting
NCT07282197 2025-12-15
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
Peking University First Hospital
Phase 2 Not yet recruiting
NCT07027124 2025-06-18
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT06435702 2024-05-30
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study
Peking University Third Hospital
Not yet recruiting
NCT06430411 2024-05-28
OLIGOMET
Medical University of Vienna
Not yet recruiting
NCT04176081 2024-01-24
SChLAP/IDC
University Health Network, Toronto
Phase 2 Not yet recruiting